Take a look at who partnered with us in 2024:


Lead Partner

Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, a universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios


Expertise Partner

ANGLE’s proven patent-protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost-effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE’s Parsortix PC1 Clinical system is cleared by the FDA for the capture and harvest of circulating tumor cells (CTCs) from metastatic breast cancer patient blood for subsequent, user-validated analysis and has a CE-IVD mark for the intended clinical use.


Expertise Partner

We share your passion for science. Promega Corporation is a world leader in providing innovative solutions for the life sciences. We develop bioluminescent technologies that deliver more biologically relevant data for small and large molecule drug discovery. Our broad life science reagent portfolio includes biochemical and cell-based assays for drug discovery targeting kinases, protein degradation, DDR/PARP, and many other hot targets such as the RAS pathway, inflammasome, and infectious disease. Let’s collaborate.


Innovation Partner

IntoDNA provides its proprietary STRIDE technology for highly sensitive, direct, in situ detection of DNA damage. STRIDE combined with comprehensive solutions and expertise supports groups that develop DDR targeted therapies. The technology can be applied to a variety of biological materials at any stage of the drug development pipeline to enrich biopharmaceutical research

Myriad Genetics 

Innovation Partner

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.


Industry Partner

Debiopharm is a privately-owned, Swiss biopharmaceutical company aiming to develop innovative therapies that target high unmet medical need in oncology and bacterial infections. Our unique business model involves the identification of high-potential compounds and technologies for in-licensing, clinically demonstrating their safety and efficacy, and then selecting global and regional pharmaceutical commercialization partners to maximize patient access. Our growing oncology drug pipeline includes the exploration of the potential of DDR inhibition in two programs: our WEE1 and USP1 inhibitors along with additional programs researching radioligand therapy and antibody drug conjugates.


Exhibition Partner

Ice Bioscience, established in 2010, provides a wide range of DDR-related services, including biochemical and functional assays targeting polymerases, helicases, nucleases, and reverse transcriptases, along with cell proliferation, apoptosis, and cell cycle detection assays. Specializing in pharmacology services, we offer comprehensive drug discovery solutions with a history of successful collaborations involving over 600 clients.

VUS diagnostics  

Event Partner

VUS Diagnostics is a genetics-focused precision diagnostic company. We combine our expertise in DDR oncology, acquired PARPi resistance, and CRISPR gene editing to support pre-clinical drug target development and improved patient stratification. Using bespoke CRISPR screens and functional variant interpretation assays, we help our clients understand drug response and resistance for the next generation of synthetic lethal treatment approaches.


Event Partner

resistanceBio specializes in creating unique drug resistance models that capture why a therapy may stop working in a patient population.  Our models track long-term evolution in non-passaged cell lines, this coupled with longitudinal multi-omic analysis helps to identify the innate and acquired mutations which allow the cancer to overcome a targeted therapy. Pharma partners armed with this knowledge allows for identification and testing of drug combinations to see if they effectively overcome and eradicate cancer.


Event Partner

We are a clinical trial and pipeline database solution designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth, and real-time information in the rapidly evolving drug development landscape. For more information or to request a demo, visit our website: